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Human pluripotent stem cells (hPSCs) provide powerful resources for application in regenerative medicine
and pharmaceutical development. In the past decade, various methods have been developed for large-scale
hPSC culture that rely on combined use of multiple growth components, including media containing various
growth factors, extracellular matrices, 3D environmental cues, andmodes of multicellular association. In this
Protocol Review, we dissect these growth components by comparing cell culture methods and identifying
the benefits and pitfalls associated with each one. We further provide criteria, considerations, and sugges-
tions to achieve optimal cell growth for hPSC expansion, differentiation, and use in future therapeutic
applications.Introduction
Human pluripotent stem cells (hPSCs), including both human
embryonic stem cells (hESCs) and human induced pluripotent
stem cells (hiPSCs) (Takahashi et al., 2007; Thomson et al.,
1998; Yu et al., 2007), represent important cell resources and
hold tremendous promise for cell-based therapies, drug discov-
ery, disease modeling, and pharmaceutical applications (Daley,
2012; Engle and Puppala, 2013). At present, more than 234
hPSC lines,which are eligible for use in federally funded research,
have been registered at the National Institutes of Health (NIH).
Numerous discussions have taken place in recent years about
standards for derivation, registries, characterization, storage,
banking, distribution, andengineeringof hPSCs for both research
and therapy (Adewumi et al., 2007; Akopian et al., 2010; Andrews
et al., 2009; Borstlap et al., 2010; Chaddah et al., 2011; Crook
et al., 2010; Panchision, 2013; Rao, 2013; Stacey et al., 2013;
Turner et al., 2013). The subsequent resources and platforms
that have emerged have opened the door to therapeutic applica-
tion for regenerative medicine and biomedical research.
In the past decade, methods for hPSC culture have evolved
rapidly in an attempt to meet the pressing needs of regenerative
medicine and drug discovery (Figure 1). Despite rapid progress
in developing new hPSC culture methods, however, we still
face many problems that need to be resolved prior to their future
application. These challenges include: (1) a lack of standardized
protocols for specific applications, (2) an absence of efficient
assays to monitor cellular stress induced by suboptimal growth
conditions and excessive apoptotic and spontaneous differenti-
ation signals during cell processing, (3) the impurity or heteroge-
neity of propagated cells (Serra et al., 2012; Stewart et al., 2006),
(4) genomic instability related to chromosomal abnormalities
(Liang and Zhang, 2013), and (5) potential tumorigenicity (Lee
et al., 2013; Malchenko et al., 2010).
In this review, we will (1) briefly describe the principles under-
lying hPSC expansion, (2) discuss current cell culture modules
and platforms for hPSC culture, (3) present basic methods forhPSC maintenance, (4) dissect new culture methods for expan-
sion of both hPSCs and differentiated cells in bioreactors, (5)
summarize practical hPSC culture methods for genetic engi-
neering and high-throughput drug screening (Table 1), and finally
(6) elucidate current challenges and highlight future directions.
Human PSCs Require Conditions Distinct from Those of
Murine PSCs
Unlike mouse embryonic stem cells (mESCs), which rely on
BMP-4 and Stat3 in the presence of leukemia inhibitory factor
(LIF) for self-renewal (Ying et al., 2003), both hESCs and hiPSCs
depend on cooperation between different signaling pathways
that are related to basic fibroblast growth factor (FGF-2), Noggin,
Activin/Nodal, and TGF-b pathways (James et al., 2005; Vallier
et al., 2005; Wang et al., 2005; Xiao et al., 2006; Xu et al.,
2005). Thus, the pluripotent states of mESCs and hPSCs are
quite different, with mESCs and hPSCs being described as
representing naive and primed pluripotent states, respectively
(Nichols and Smith, 2009; Ying et al., 2008). Phenotypically,
mESCs can passage and grow as single cells, whereas hPSCs
have a drastic loss of viability after enzymatic dissociation as
single cells. Thus, hPSCs are generally plated as clumps and
grow as colonies and aggregates. Therefore, the genetic and
phenotypic differences betweenmESCsandhPSCs have neces-
sitated different culturemodules to support hPSC growth in vitro.
Interestingly, the use of LIF with two inhibitors (GSK-3bi and
ERK1/2i, abbreviated as 2i) that suppress glycogen synthase
kinase-3b (GSK-3b) and extracellular signal-regulated kinases
1/2 (ERK1/2) supports naive mESC growth under feeder-free
conditions in defined medium (Ying et al., 2008). Recently, Gafni
et al. (2013) reported direct conversion of primed hPSCs to the
naive state using naive human stem cell medium (NHSM) that
contains LIF and 2i. These naive hPSCs had an approximately
40% increase in single-cell cloning efficiency. Through a dif-
ferent screening strategy for small molecule inhibitors that sup-
port naive pluripotency in hPSCs, Chan et al. (2013) identifiedCell Stem Cell 14, January 2, 2014 ª2014 Elsevier Inc. 13
Figure 1. Timeline of the Development of Cell Culture Modules for hPSCs and Future Directions (Year 2014 to 2016)
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gene expression signature for native preimplantation epiblasts,
thus demonstrating another method for converting hPSCs to a
naive state. Hence, manipulation of pluripotent states through
perturbation of growth factor signaling enhances single-cell
plating efficiency, which has greater potential for both genetic
engineering and hPSC expansion.
Key Contributing Factors in hPSC Culture
The growth of any type ofmammalian cell in vitro requires growth
media, extracellular matrices, and environmental factors. Here,14 Cell Stem Cell 14, January 2, 2014 ª2014 Elsevier Inc.we will discuss three key factors that influence the quality,
robustness, and utility of various hPSC culture methods: (1)
growth medium, (2) extracellular matrices, and (3) environmental
cues (e.g., a growth environment in a bioreactor) (Table 1).
Ideally, the information about various cell culture components
described here can be used to formulate new and tailored proto-
cols for specific uses.
Growth Medium Development for hPSC Culture
Growth medium is one of the most critical components of hPSC
culture and has undergone a dynamic evolution since it was
initially used for hESC culture (Thomson et al., 1998). The
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xeno-free, and chemically defined medium, suitable for support-
ing the growth of almost all types of hPSC lines (Figure 1). The
first generation of hESC medium commonly contained fetal
bovine serum (FBS) and undefined/conditioned secretory com-
ponents from mouse embryonic fibroblasts (MEFs). In recent
years, scientists have established more standardized and
better-definedmedium to replace xenogeneic elements inmedia
(Genbacev et al., 2005; Li et al., 2005). Vallier et al. (2005) used
chemically defined medium with Activin A, Nodal, and FGF-2
to propagate hESCs. The Knock-Out Serum Replacement
(KSR) is widely used with FGF-2 to support feeder-based
hPSC culture, and a defined culture medium (termed TeSR1)
containing FGF-2, lithium chloride (LiCl), g-aminobutyric acid
(GABA), TGF-b, and pipeolic acid was developed by Thomson
and colleagues for use in feeder-free conditions (Ludwig et al.,
2006). More recently, Thomson and coworkers developed
chemically defined E8 medium (E8), which is a derivative of
TeSR1 containing eight components that lacks both serum
albumin and b-mercaptoethanol. This E8 medium, combined
with EDTA passaging, may be suitable for culturing a broad
range of hiPSC and hESC lines, particularly to improve episomal
vector-based reprogramming efficiencies as well as experi-
mental consistency (Chen et al., 2010b, 2011b).
Extracellular Components
Extracellular components include diverse organic matrices
from animal cells, hydrogel, individual matrix proteins, synthetic
surfaces, and some commercially well-defined and xenoge-
neic-free components. The commercially available products
include CELLstart, which contains components only of human
origin (Invitrogen), StemAdhere, which has defined matrix with
human proteins produced in human cells under completely
defined conditions (Primorigen Biosciences), and Synthemax-
R Surface, a unique synthetic peptide acrylate-coating surface
(Corning).
Matrigel. Thus far, Matrigel has been one of the most widely
used extracellular components for feeder-free culture of hPSCs.
It is a basement membrane matrix, rich in types I and IV colla-
gens, laminin, entactin, heparan sulfate proteoglycan, matrix
metalloproteinases, undefined growth factors, and chemical
compounds (Kleinman et al., 1982, 1983; Mackay et al., 1993;
Vukicevic et al., 1992). Although it is widely used for research
purposes, it is important to note that Matrigel, which is a semi-
chemically defined, xenogeneic substrate, cannot be used for
generation of clinical-grade hPSCs.
Extracellular Matrix (ECM) Proteins. Many ECM proteins are
developmentally regulated, and some can be used to support
hPSC self-renewal or lineage commitment (Braam et al.,
2008c; Rodin et al., 2010; Xu et al., 2001). Recombinant vitronec-
tin is a defined substrate that sustains hESC self-renewal
through adhesion with aVb5 integrin (Braam et al., 2008c). There
is also increasing evidence showing that specific laminin iso-
forms (expressed in postimplantation embryos) may play an
important role in sustaining long-term hPSC growth. By plating
hPSC cell clumps on cell culture dishes coated with the human
recombinant laminin-511 (LM-511), Tryggvason and colleagues
found that this single laminin isoform maintained self-renewal
of normal hPSCs for more than 20 passages (Rodin et al.,
2010). This laminin isoform-based protocol is free from animalproducts and feeders with only a single undefined component
(i.e., human albumin), producing homogeneous hPSCs that are
suitable for future therapeutic use (Rodin et al., 2010). Unfortu-
nately, the current use of laminin for both hPSC maintenance
and expansion is limited due to the high cost of obtaining highly
purified proteins. Newmethods that utilize synthetic surfaces are
being developed to simulate the effects of ECMproteins (such as
laminin) on hPSC growth.
Synthetic Surfaces. It is feasible that synthetic surfaces could
mimic major signal transduction pathways that are required for
hPSC growth. Synthetic surfaces that modulate TGF-b signaling
can influence TGF-b-related cell fate decisions (Li et al., 2011),
and surface arrangement of properly condensed peptides
(e.g., laminin peptides) define new 3D synthetic scaffolds that
support hPSC growth (Derda et al., 2007). Moreover, modifica-
tions of cell growth surfaces with simplified techniques could
facilitate the development of chemically defined conditions to
expand clinically relevant hPSCs at low cost. For example,
Jaenisch and coworkers modified a cell culture plastic sur-
face by UV/ozone radiation, producing significantly improved
hPSC numbers under fully defined conditions. There was a
3-fold increase in hPSC numbers compared with feeder-based
culture (Saha et al., 2011). Several groups have also designed
new surface substrates based on a high-affinity cyclic argi-
nine-glycine-aspartate (RGD) peptide that contains the RGD
integrin recognition sequence (Kolhar et al., 2010), synthetic
peptide-acrylate surfaces (Melkoumian et al., 2010), and
synthetic polymer coating with poly[2-(methacryloyloxy)ethyl
dimethyl-(3-sulfopropyl)ammonium hydroxide] (PMEDSAH)
(Villa-Diaz et al., 2010) for long-term maintenance of hPSCs.
Thus, advanced material technology could offer fully synthetic
environmental cues that sustain long-term culture of clinical-
grade hPSCs.
Environmental Cues
There are a number of environmental cues, including cues from
both physical and physiological environments (besides the cells,
growth medium components, and ECM), that encourage hPSC
growth, such as temperature, humidity, osmosity, acidity, rigidity
of growth surfaces, cell density, gas diffusion exchange, and
modes of multicellular associations. Among these various fac-
tors, we will highlight the consumption of oxygen (O2) and the
modes of multicellular associations, which are two key factors
that influence hPSC growth.
The physiological environment of early-stage mammalian
embryo development is hypoxic. hESC culture needs to be
designed to maximally mimic this in vivo condition. However,
conventional hESC culture has been traditionally implemented
under normoxia (i.e., 21% O2). Low O2 tension (2%–3% O2)
at physiological levels prevents spontaneous differentiation of
hESCs (Ezashi et al., 2005). Moreover, physiologic O2 (2%)
also enhances hESC clonal recovery by 6-fold and reduces
spontaneous chromosomal abnormalities without affecting
expression of pluripotency markers in both WA01 (H1) and
WA09 (H9) hESCs (Forsyth et al., 2006). Telomere length in
some hESCs lines (e.g., WA09 cells) is more sensitive to oxida-
tive stress than others (e.g.,WA01 cells) under normoxia (Forsyth
et al., 2006). Thus, optimal O2 levels would be required to main-
tain genomic integrity, which should be further validated for
hPSC expansion under different growth conditions.Cell Stem Cell 14, January 2, 2014 ª2014 Elsevier Inc. 15
Table 1. Summary of Cell Culture Methods for Undifferentiated and Differentiated hPSCs
Methods and
Applications Advantages Disadvantages Applications Key References
Colony-type cultures
(CTCs)
on MEF feeder well characterized, predicative
outcomes, supports various
hPSC line growth, economical
xenogeneic feeder, undefined,
variability in components, labor-
intensive and time-consuming
SCM, RES, DA, hPSC line
derivation, single-cell cloning
Thomson et al., 1998
on human feeders xeno-free, clinical-grade hESC
derivation
undefined components, variability
in culture
SCM, RES, DA, cell-based
therapeutics
Richards et al., 2002
on Matrigel feeder-free xenogeneic, partially defined
components, variability in culture
SCM, RES, DA Xu et al., 2001
on vitronectin xeno-free, chemically defined
components
lower efficiency SCM, RES, DA, cell-based
therapeutics
Braam et al., 2008c
on laminin isoform 511 xeno-free, chemically defined
components
low yield of purified laminin protein,
expensive
SCM, RES, DA, cell-based
therapeutics
Rodin et al., 2010
on synthetic surfaces xeno-free, chemically defined
substrates, economical
N/A SCM, RES, DA, cell-based
therapeutics, small-scale
hPSC expansion
Saha et al., 2011
general comments conventional methods for hPSC
culture, de novo hPSC line
derivation, compatible with
many growth conditions,
sustains pluripotent states, high
differentiation potential, does
not require single-cell dissociation
steps, does not require small
molecules for passaging
low recovery rates from
cryopreservation, reported
chromosomal abnormalities, low
transfection rates (3%–35%), low
efficiency for transduction,
heterogeneity and variability; not
ideal for single-cell analysis,
high-throughput (HTP) assays,
and hPSC expansion
hPSC maintenance, hPSC
banking, research-grade
experiments, lineage
differentiation, non-HTP drug
assays, single-cell cloning,
EB derivation, pluripotent
state conversion
Thomson et al., 1998;
Richards et al., 2002;
Xu et al., 2001; Braam
et al., 2008c; Rodin et al.,
2010; Saha et al., 2011;
Liew et al., 2007; Braam
et al., 2008a, 2008b; Chen
et al., 2012a; Mallon et al.,
2006; Hanna et al., 2010
Non-colony-type
monolayer (NCM)
on Matrigel high plating efficiency, robustness,
high cell yield related to colony
culture, high efficiency for genetic
manipulation
xenogeneic, uses various small
molecules (e.g., ROCKi and JAKi)
for single-cell plating
SCM, RES, HTP assays, hPSC
expansion, cryopreservation
Chen et al., 2012a
on Matrigel uses ROCKi only for initial cell
passages, high pluripotency
observed in some hPSC lines SCM, RES, HTP assays,
cryopreservation
Kunova et al., 2013
general comments higher scalability and cell production,
consistent growth rates: 3-day
culture, relatively homogeneous cells,
compatible with xeno-free cultures,
high recovery rates after thawing
cells, versatile for transfection and
transduction
lower cell production than SC,
reported chromosomal abnormalities,
potential selection pressure for
mutated cells
hPSC expansion, cell banking,
cell-based therapeutics, genetic
manipulation
Chen et al., 2012a;
Kunova et al., 2013
(Continued on next page)
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Table 1. Continued
Methods and
Applications Advantages Disadvantages Applications Key References
Suspension culture
(SC)
clump inoculation feeder- and matrix-free heterogeneity of aggregates EB differentiation Gerecht-Nir et al., 2004
clump inoculation optional use of ROCKi intermediate cell expansion cell-based therapeutics Amit et al., 2010
single-cell inoculation controllable size of aggregates,
demonstrated high cell yield
long-term use of ROCKi hPSC expansion, cell-based
therapeutics
Krawetz et al., 2010;
Chen et al., 2012b
single-cell inoculation early development of SC in hPSCs,
controllable size of aggregates
relative lower cell production hPSC expansion, cell-based
therapeutics
Steiner et al., 2010
SCMC adjustable growth areas, reduced
shear-force damages, demonstrated
high cell yield, different microcarriers
variability of MC attachment,
requires coating with MC, requires
cell dissociation with MC
hPSC expansion, cell-based
therapeutics
Lock and Tzanakakis 2009;
Fernandes et al., 2009; Oh
et al., 2009
SCMC_ME better designs of shear-force
protection, various, economical
encapusulations
compromized cell production,
decapsulation steps necessary,
increased complexity
hPSC expansion, cell-based
therapeutics
Serra et al., 2011
general comments feeder- and/or matrix-free, high
hPSC expansion rates, compatible
with spinner flasks/bioreactors,
growth conditions can be monitored,
controllable autocrine and paracrine,
compatible with MC, ME, or both,
microversion available: microfuidic
bioreactors, cellular plasticity between
SC and CTC
agitation-induced shear force,
altered gene expression patterns,
increased heterogeneity,
compromised pluripotency,
cell loss after mechanical
passaging, requires ROCKi for
single-cell or small clump
passaging, variability in expansion
rates, not ideal for HTP screening
hPSC expansion, cell-based
therapeutics, cell transplantation,
organogenesis
Gerecht-Nir et al., 2004;
Amit et al., 2010; Krawetz
et al., 2010; Chen et al.,
2012b; Steiner et al., 2010;
Lock and Tzanakakis 2009;
Fernandes et al., 2009;
Oh et al., 2009; Serra et al.,
2011; Ungrin et al., 2008;
Siti-Ismail et al., 2008;
Zweigerdt et al. 2011;
Serra et al., 2012; Villa-Diaz
et al., 2009
DA, low-throughput drug assay; EB, embryoid body; HTP, high-throughput assay; JAKi, JAK Inhibitor 1; MC, microcarriers; ME, microencapsulation; N/A, not determined; RES, research
experiments; ROCKi, ROCK inhibitors; SC, suspension culture; SCM, stem cell maintenance; SCMC, suspension culture combinedwithmicrocarrier (MC); SCMC_ME, suspension culture combined
with both microcarrier (MC) and microencapsulation (ME) methods.
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tion are primarily physical properties of intercellular interactions.
However, these physical properties have a significant impact on
cell density, ligand-receptor interactions, signal gradient pro-
cessing, intracellular signal transduction, and the microenviron-
ments of hPSCs. Conventionally, hESCs are grown on MEFs or
on Matrigel as colonies and differentiate as embryoid body
(EB) aggregates. With the discovery of single-cell death and sur-
vival mechanisms (Androutsellis-Theotokis et al., 2006; Chen
et al., 2010b; Ohgushi et al., 2010; Watanabe et al., 2007), we
can now grow hPSCs in different modes such as colonies
(Thomson et al., 1998), single cells (Tsutsui et al., 2011), single-
cell-based non-colony-type monolayer (NCM) (Chen et al.,
2012a; Kunova et al., 2013), and suspended aggregates
(Gerecht-Nir et al., 2004; Steiner et al., 2010; Ungrin et al.,
2008). The choice of a specific mode for hPSC growth would
depend on individual research aims and pharmaceutical or
clinical applications.
hPSC Maintenance Methods Should Be Tailored for
Different Uses
Maintaining high-quality hPSCs is essential because all subse-
quent applications would depend on the starting materials.
Large-scale maintenance of these cells is usually not necessary
in the research environment. In general, with respect to different
usages of the cells, corresponding methods should be adjusted
in order to reduce the workload and cost.
Feeder-Based Culture of hPSC Colonies Is Suitable for
Routine Maintenance
MEFs are the most frequently used feeder cells because they
support robust growth of all types of ESCs as colonies (Mallon
et al., 2006; Thomson et al., 1998). However, since MEFs have
complex, undefined, and xenogeneic properties, various human
cell types have been substituted to support hESC growth,
including hESC derivatives. Bongso and colleagues initially re-
ported that human fetal and adult fibroblast feeders support
long-term undifferentiated growth of hESCs (Richards et al.,
2002). Human cells from adult tissues such as fallopian tube,
foreskin, marrow-derived stromal cells, and uterine endome-
trium have all been exploited to expand hESCs (Mallon et al.,
2006). The use of feeders is suitable for routine hPSC mainte-
nance, genetic engineering, and single-cell cloning. However,
feeder cultures are not designed for clinical application, as
they could be potentially problematic due to the introduction of
undefined factors into cultures.
Feeder-Free Culture of hiPSC Colonies Provides
Well-Defined Conditions
Considerable effort has been made to develop feeder-free con-
ditions with defined medium such as KSR supplemented with
Activin A and FGF-2, which was found to support undifferenti-
ated self-renewal of hESCs (Xiao et al., 2006). FGF-2 and sup-
pression of BMP signaling sustain the pluripotent state of hESCs
(Xu et al., 2005) and is often used to support undifferentiated
growth of hESCs under feeder-free conditions (Wang et al.,
2005). Despite the presence of animal-derived components in
KSR, it was still employed to derive six clinical-grade hESC lines
(Crook et al., 2007). It would be interesting to compare these
lines to the next generation of clinical-grade hESC lines, which
have been derived under completely xeno-free conditions.18 Cell Stem Cell 14, January 2, 2014 ª2014 Elsevier Inc.De Novo Xeno-Free Culture Is Required for Clinical
Application
Complete xeno-free derivation and maintenance of hESCs is an
enormous task because it requires implementation of xeno-free
practices at every step during the derivation process, including
mechanical isolation of the ICM, use of human feeder cells,
and propagation andmaintenance in xeno-free definedmedium.
This approach is designed for clinical application and, due to its
time-consuming nature, may not be suitable for some research
experiments.
Overall, quality control of hPSC culture is a paramount issue
because these maintained cells could potentially be used for
clinical applications and for many important assays involved in
drug development. Alterations in cellular states and identities
are certain to affect therapeutic outcomes and data interpreta-
tion. Therefore, periodic examination is recommended to verify
gene expression profiles, gene copy numbers, and chromo-
somal integrity (reviewed in Baker et al., 2007; Lee et al., 2013;
Pistollato et al., 2012).
Suspension Cultures Enable Large-Scale Production of
hPSCs
Generation of clinically relevant quantities of hPSCs, ranging
from 107–1010 or beyond, is essential for their clinical use. Sus-
pension culture in bioreactors provides a promising platform to
robustlymanufacture hPSCproducts for this purpose. Generally,
hPSCs expanded by suspension culture in bioreactors remain
pluripotent and chromosomally stable. Among many types of
bioreactors, spinner vessels and stirred-tank bioreactors are of
particular interest. These bioreactors are equipped with a glass
vessel having a working volume from 50 ml to 200 l and an
impeller to provide a homogeneous growth environment and
allow efficient gas and nutrient transfer (Serra et al., 2012). These
machines can precisely control culture conditions by real-time
monitoring of temperature, O2 levels, acidity or basicity, auto-
crine levels, growth factor consumptions, and metabolite con-
centrations. Technically, suspension culture can be performed
in several ways, including aggregated hPSC clumps, hPSCs im-
mobilized on microcarriers, and microencapsulation.
At present, there are no consensus views on how to assess the
growth rates of various expansion protocols because they are
implemented in different laboratories. To facilitate the compari-
son among various growth rates generated from different labora-
tories, we would like to introduce a simple parameter: fold
increase in cell number per day (abbreviated as FIPD) for any
given number of days of culture. The concept of FIPD provides
a quick analysis of growth rates of propagated cells (Table 2).
However, we also need to point out that there are many con-
founding variables involved in the regulation of cell growth rates.
Furthermore, the changes of growth rates are a dynamic pro-
cess, which vary with initial inoculated cell density and the
modes of multicellular association. So, we also recommend
that researchers examine the FIPD along with other parameters
such as cell doubling times as well as the entire growth curves
when comparing between different protocols.
Suspension Culture of hPSC Aggregates versus
Single-Cell Inoculation
Stirred-suspension bioreactors or spinner flasks were originally
used for passaging human EBs (Dang et al., 2004; Gerecht-Nir
Table 2. Summary of Cell Growth Rates in Different hPSC Culture Methods
Cell Culture Inoculation MC/ME Bioreactors Cells FIPD References
SC single cells N/A bioreactor hESCs 4.2 Krawetz et al., 2010
SC single cells N/A spinner flask WA09 4.2 Chen et al., 2012b
SC clumps N/A Erlenmeyer hPSCs 2.5 Amit et al., 2010
SC clumps N/A STLV hESC EBs 2.5 Gerecht-Nir et al., 2004
SC single cells N/A spinner flask hiPSCs 1.5 Zweigerdt et al., 2011a
SC single cells N/A spinner flask hiPSCs 0.9 Zweigerdt et al., 2011a
SC single cells N/A spinner flask hESCs 0.7 Steiner et al., 2010
SC clumps N/A spinner flask hESC EBs 0.7 Cameron et al., 2006
SC clumps N/A spinner flask+gbi hESC EBs 0.6 Yirme et al., 2008a
SC clumps N/A spinner flask+pi hESC EBs 0.2 Yirme et al., 2008a
SC clumps N/A STLV + pi hESC EBs 0.1 Yirme et al., 2008a
SCMC clumps MG-polystyrene spinner flask hESCs 5.6 Lock and Tzanakakis, 2009a
SCMC clumps MG-polystyrene spinner flask hESCs 4.3 Lock and Tzanakakis, 2009a
SCMC clumps MG-DE53 spinner flask HES-3 2.0 Chen et al., 2011aa
SCMC clumps MG-DE53 spinner flask HES-2 1.0 Chen et al., 2011aa
SCMC clumps nc-Cytodex 3 spinner flask hESCs 0.5 Fernandes et al., 2009
SCMC clumps MG-cellulose spinner flask HES-3 4.0 Oh et al., 2009a
SCMC clumps MG-Cytodex 3 ULAP hESCs 1.3 Nie et al., 2009
SCMC_ME single cells plus alginate spinner flask hPSCs 1.0 Serra et al., 2011a
SCMC_ME single cells no alginate spinner flask hPSCs 0.4 Serra et al., 2011a
Static SC clumps LM-polystyrene ULAP HES-3 1.2 Heng et al., 2012a
Static SC clumps VN-polystyrene ULAP HES-3 1.2 Heng et al., 2012a
Static SC clumps MG-cellulose N/A HES-3 1.0 Oh et al., 2009a
Static NCM single cells N/A N/A hPSCs 1.0 Chen et al., 2012aa
Static SC single cells Hillex II ULAP hESCs 0.6 Phillips et al., 2008
Static colonies clumps N/A N/A hPSCs 0.4 Chen et al., 2012aa
The growth rates are evaluated by fold increase (relative to the initial seeding cells) in cell number per day (i.e., FIPD). Representative studies are shown.
Clumps, hPSC clump inoculation; gbi, glass ball impeller in spinner flasks; LM-polystyrene, laminin-coated polystyrene; MG-polystyrene, Matrigel
coated with polystyrene; nc-Cytodex 3, not coated with the microcarrier Cytodex 3 as control in the study; N/A, not available; NCM, single-cell-based
noncolony monolayer culture; pi: paddle impeller in spinner flasks; SC, suspension culture; SCMC, suspension culture combined with microcarrier
(MC); SCMC_ME, suspension culture combined with both microcarrier (MC) and microencapsulation (ME) methods; STLV, slow-turning lateral
vessels; ULAP, ultra-low attachment plates from Corning; VN-polystyrene, vitronectin-coated polystyrene.
aPair-wise designs for comparative studies in the same study or publication.
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(Fok and Zandstra, 2005). Recently, this method has been
increasingly used for expansion of undifferentiated hPSCs
(Amit et al., 2010; Steiner et al., 2010), resulting in various culture
methods (Table 2). Routinely, there are two ways of seeding cells
for hPSC-aggregated cultures: clump versus single-cell inocula-
tion. One of the major problems of clump inoculation is that it is
difficult to control the size of hPSC clumps, thus leading to
increased apoptosis or spontaneous differentiation.
Single-cell inoculation for suspension culture, using the ROCK
inhibitor Y-27632, appears to be one way to control the size of
hPSC aggregates. The key steps of single-cell inoculation have
been previously outlined (Steiner et al., 2010). However, this
reported method had a lower expansion rate (FIPD = 0.7, based
on the outcome from 1 week of cell culture compared with
colony-type growth on feeders; Table 2). Moreover, suspension
culture resulted in 58% cell loss after mechanical cell passaging
whereas colony passaging had only 24% cell loss in the same
study (Steiner et al., 2010). To improve cell expansion rates insuspension culture, Rancourt and coworkers used a modified
single-cell inoculation method, by which single cells form aggre-
gates in mTeSRmedium containing ROCK inhibitor and rapamy-
cin in bioreactors for 24 hr (Krawetz et al., 2010). The presence of
rapamycin inhibits the appearance of differentiated cells and
enhances cell vitality in cell aggregates. They were able to obtain
4.2-FIPD in 6 days (Krawetz et al., 2010). Similar expansion rates
have been achieved using single-cell inoculation of ESCs and
iPSCs in different conditions (Chen et al., 2012b; Zweigerdt
et al., 2011). Interestingly, the suspended cells resembled ‘‘EB-
like’’ clusters in terms of morphology, but they maintained the
pluripotent state. Importantly, the epithelial properties of hPSCs
were restored after replating these aggregates on feeders, indi-
cating the existence of both flexibility and reversibility within
hPSCs under different growth modes.
Benefits and Pitfalls of Suspension Culture
In general, suspension culture with spinner flasks can sig-
nificantly increase aggregated hPSC production without the
use of feeders. The scalability of this culture may be crucial toCell Stem Cell 14, January 2, 2014 ª2014 Elsevier Inc. 19
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advantage is its naturally formedmulticellular microenvironment,
which may enable hPSCs to retain high differentiation capacity.
In contrast, hydrodynamic shear-force-related cellular damage
presents a major limitation of this method (Serra et al., 2012).
Another drawback involves the variability of growth rates that
exist in different suspension cultures, possibly due to the hetero-
geneous sizes of aggregates. As cell aggregates increase in size
and in irregularity, they may induce apoptosis-related cell loss,
cellular differentiation, and heterogeneity. To avoid the formation
of large aggregates, optimal cell inoculation methods and
passaging schedules should be determined. In addition, the
long-term effects of ROCK inhibition on hPSCs remain to
be evaluated. Finally, heterogeneity induced by spontaneous
differentiation may be due to the sensitivity of some hESC lines
(e.g., HES-3 and IMR90) to shear force (Leung et al., 2011).
With regard to this problem, porous microcarriers might reduce
or overcome shear-force-related problems.
Suspension Culture with Microcarriers Controls
Aggregation
The demonstration thatmESCs can be immobilized onmicrocar-
riers and propagated in bioreactors (Fok and Zandstra, 2005)
provides a proof of principle for using microcarriers as a simple
and scalable way to control cellular aggregation in hPSC sus-
pension culture. Various porous and nonporous carriers with
matrices are commercially available (Chen et al., 2011a; Nie
et al., 2009). They greatly enhance the surface area for cell
adherence and gas diffusion. Adjustable surface area for cell
growth reduces the consumption of medium and growth factors,
thus having potential for future clinical development. Microcar-
riers such as coated polystyrene (Heng et al., 2012; Phillips
et al., 2008), large positively charged spherical Cytodex 3 (Fer-
nandes et al., 2009; Fok and Zandstra, 2005; Nie et al., 2009),
and positively charged cylindrical cellulose (i.e., DE52, DE53,
and QA52) (Chen et al., 2010a, 2011a; Oh et al., 2009) have
high attachment efficiency and sustain the pluripotency of
hPSCs (Table 2). Gradual loss of pluripotency has been
observed in hESCs grown on uncoated microcarriers for contin-
uous passaging, and thus either Matrigel or laminin coating is
critical for stable expansion of undifferentiated hESCs attached
on various microcarriers. Taken together, current studies indi-
cate that individual components such as laminins can replace
Matrigel for microcarrier coating. However, dissociation of the
cells from the carriers is also needed. Therefore, economically
compatible and degradable microcarrier beads need to be
developed. Despite the protective nature of microcarriers, there
is still a need to control the size of cell aggregation.
Microencapsulation Protects hPSCs in Culture and
during Cryopreservation
Microencapsulation of cells in hydrogels has also been devel-
oped to avoid the shear-force microenvironment and excessive
clump agglomeration in suspension culture (Murua et al., 2008).
Important considerations for designing this microenvironment
include the biocompatibility and biosafety of a specific material
(e.g., calcium alginate and hyaluronic acid) and the ability to
mimic in vivo embryonic niches. Microencapsulation of hESCs
in 1.1% calcium alginate capsules enabled prolonged feeder-
free expansion and maintenance of the pluripotent state (more
than 8 months) in static culture (Siti-Ismail et al., 2008). This20 Cell Stem Cell 14, January 2, 2014 ª2014 Elsevier Inc.method is being considered as a tool for integrating expansion
with cryopreservation of hPSCs (Siti-Ismail et al., 2008). Indeed,
hPSCs immobilized on microcarriers and encapsulated in algi-
nate in stirred tank bioreactors exhibited high cell recovery rates
(>70%) after cryopreservation, which were 3-fold higher than
nonencapsulated cells (Serra et al., 2011). A 19-fold increase in
cell concentration was found in encapsulated hPSCs, equivalent
to 1.0-FIPD in 20-day culture, whereas only a 7.5-fold increase
(FIPD = 0.4) was produced in the cells without alginate microen-
capsulation (Serra et al., 2011). Clearly, this method shares
many advantages with porous microcarriers in terms of cell
protection, enhanced surface areas, scalability, and reproduc-
ibility. Notably, the diffusion of cell mass and gas and monitoring
of cell growth inside the capsule are limited by the physical prop-
erties of encapsulation. In addition, a decapsulation process is
required to harvest the cells.
In summary, the benefits of culturing hPSCs by stirred-sus-
pension bioreactors could be substantial. Problems frequently
encountered with suspension cultures include the properties of
microcarriers, the microenvironmental setting of bioreactors,
cell passage methods, the use of small molecules, growth rate
control, and differentiation pressure. Many issues need to be
resolved prior to further clinical application. In this regard, it is
necessary to compare suspension culture methods with other
emerging and complementary methods.
Cell Culture Platforms for Assaying hPSCs
NCM Expansion Enables Downstream Analysis
Owing to several major limitations (e.g., induced heterogeneity
and suspended growth), neither colony-type nor suspension
culture is suitable for drug screening or single-cell analysis. In
response to this unmet need, scientists have developed a
single-cell based NCM culture (Chen et al., 2012a; Kunova
et al., 2013). The key step in this method comprises seeding
dissociated cells (single cells) at high density (i.e., 1.4 3
105/cm2) on Matrigel-coated polystyrene plates in the presence
of ROCK inhibitor (Y-27632) or JAK Inhibitor 1 to facilitate the
initial 24 hr single-cell plating efficiency and to prevent the forma-
tion of colonies (Chen et al., 2012a). Alternatively, hPSCs can be
cultivated as NCMs on human recombinant laminin-521-coated
polystyrene surfaces without the use of ROCK inhibitors. Gener-
ally, hPSCs under these growth conditions remain chromoso-
mally normal, pluripotent, and differentiable into adult tissues
of the three germ layers (Chen et al., 2012a).
The advantages of this culture method include: feeder-free,
controllable growth rates, generation of homogeneous hPSCs,
robust cell production (i.e., 1.0-FIPD in 4-day culture), and
rapid (2- to 4-day) cell recovery from cryopreservation compared
with frozen cells from colony-type culture, which usually take 1 to
3 weeks to recover (Chen et al., 2012a). Notably, hPSCs grown
as NCMs are very efficient at forming teratomas and are revers-
ible to colony-type culture when the cells are plated as clumps
on MEF feeders (Kunova et al., 2013). After adaptation to NCM
culture in the presence of ROCK inhibitor (Y-27632) during initial
passages, some hPSC lines could be passaged as NCMs
without the inhibitor (Kunova et al., 2013). This method is also
easy to manage and particularly suitable for genetic engineering
and high-throughput drug screening (Chen et al., 2012a). How-
ever, long-term dissociated culture might select variant cells
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genomic stability of hPSCs at chromosomal and subchromoso-
mal levels should be carried out to compare cells cultured as
colonies, in suspension, and as NCMs.
Cell Culture Methods for Improved Genetic Engineering
Both transfection and transduction of cells with geneticmaterials
of interest via various expression systems are efficient ways to
investigate the functionality of RNAs and/or proteins. However,
hPSCs from conventional colony-type culture are difficult to
transfect or transduce, resulting in a greater variability in trans-
fection/transduction efficiencies (Braam et al., 2008a, 2008b;
Chen et al., 2012a; Liew et al., 2007). Notably, transfection effi-
ciency was greatly improved when the cells were enzymatically
dissociated (Braam et al., 2008a). Furthermore, when cells
were dissociated and replated as a high-density monolayer,
shRNAs, microRNAs, oligonucleotides, plasmid DNAs, and
lentivirus were successfully introduced into hPSCs with high
efficiency (Chen et al., 2012a; Padmanabhan et al., 2012).
High-density single-cell plating in the presence of the ROCK in-
hibitor Y-27632 enables the hPSCs to form loosely packed cell
clusters within 24 hr, which might facilitate the uptake of
DNAs, RNAs, and lentiviruses (Chen et al., 2012a).
Microfluidic Bioreactors Allow Precise Manipulation of
Environmental Cues
Microfluidic bioreactors (known as microbioreactors, biochips,
and cell-chips) are a microscale version of conventional bioreac-
tors (macrobioreactors). Microfluidic bioreactors integrate many
monitoring and control features used by macrobioreactors,
which include electrical signals and fluidic, hydrodynamic shear,
and optical components (Cimetta et al., 2009). Microfluidic bio-
reactors have shown their potential to establish highly control-
lable microenvironmental cues. The 3D niche likely mimics the
in vivo microenvironments, including the spatial orientations of
cells and ECM, the temporal control of the concentration
gradient of soluble factors, and the availability of both O2 and
carbon dioxide (Cimetta et al., 2009).
Microfluidic bioreactors have been applied to study stem cell
behaviors in the 3D microenvironment in real time, to analyze
single-hESC-derived colonies (Villa-Diaz et al., 2009), and to
quantitatively control signaling trajectories contributed by both
autocrine and paracrine in individual hPSCs (Moledina et al.,
2012). Scientists have also created 3D vascular structures to
examine the effects of drugs and to investigate the interactions
between different types of vascular cells (van der Meer et al.,
2013). Obviously, cellular and tissue model systems developed
by microfluidic bioreactors may have broad applications in
drug screening, cellular assay, and tissue engineering.
Suspension Cultures Enable Expansion of
Differentiated Cells
The clinical application of hPSCs (e.g., cell-based replacement
and drug screening) will rely on our ability to obtain sufficient
numbers of functional mature cells. Therefore, expansion of
such large amounts of desired cells is of utmost importance.
Scaled-up expansion could bemade possible in suspension cul-
ture or in NCM formats. Currently, functionally differentiated cells
can be obtained through multiple intermediate or precursorstages. Frequently, hiPSCs are expanded as EBs or precursors
at the three-germ-layer stage. Occasionally, these cells are
expanded to generate terminally differentiated cells. In an early
report, hESC EBs were cultivated in a slowly turning lateral
vessel (STLV) bioreactor, resulting in a 70-fold increase in cell
concentrations in 28-day culture (Gerecht-Nir et al., 2004). To
optimize growth conditions, Itskovitz-Eldor and colleagues
found that a spinner flask with the Glass Ball Impeller had a
higher EB yield, a more homogenous shape, and a faster
growth rate than a spinner flask with a paddle impeller and
STLV bioreactor (Yirme et al., 2008). This simple comparison
highlights the importance of mechanical stirring-force distribu-
tion, an easily ignored problem, in influencing the proliferation
of differentiated EBs.
With respect to ectodermal lineage expansion, Reubinoff and
coworkers reported direct conversion of hESC suspension
culture into neural precursor spheres (Steiner et al., 2010).
Furthermore, these hESC precursors could be differentiated in
suspension into a highly enriched cell population for generating
neurons that express b-III tubulin, tyrosine hydroxylase (TH),
GABA, and glutamate, astrocytes that express glial fibrillary
acidic protein (GFAP), and NG2-expressing oligodendrocyte
progenitors (Steiner et al., 2010).
To expand the cells toward mesodermal lineages, hESC
EBs (2 to 3 3 105 cells/ml) propagated in spinner flasks pro-
duced a 15-fold increase in EB-derived cells in 21 days, which
produced CD34+/CD31+ hematopoietic progenitors (5%–6%)
on day 14, comparable to the differentiation capacity of EB-
derived cells under static culture (Cameron et al., 2006). Using
a controlled fed-batch media dilution approach, Csaszar et al.
(2012) demonstrated that they could control inhibitory feedback
signaling, thus rapidly amplifying human cord blood cells
ex vivo, producing an 11-fold increase in functional HSCs (in
12-day culture; FIPD = 0.92). The ex vivo expanded HSCs
exhibited the default capacities such as self-renewing and
multilineage differentiation. This study offers strategies to
expand primary cell culture ex vivo and also demonstrates
the feasibility of multistep expansion of such hematopoietic lin-
eages de novo from hPSC-derived progenitor cells in such a
controlled system.
For cardiac differentiation, Lecina et al. reported that hESCs
grown on laminin-coated TOSOH-10 in ultra-low attachment
plates generatedmore than 80%beating aggregates, or approx-
imately 60% cardiomyocyte conversion related to the initial
numbers of seeded hESCs (Lecina et al., 2010). To expand
cardiomyocytes on a large scale, Zandstra and colleagues
employed a microprinting strategy to generate size-specified
aggregates in an O2-controlled bioreactor (Niebruegge et al.,
2009). This integrated approach enabled them to reduce the het-
erogeneity of cell aggregates and facilitated stirred bioreactor
expansion of hPSCs as well as mesodermal differentiation.
Under hypoxia (4% O2), approximately 48.8% of cardiomyo-
cytes were generated, as opposed to 19% contracting EBs
under conventional dish culture (Niebruegge et al., 2009).
Concerning expansion of endodermal progenitors, it is also
feasible to expand and differentiate hESCs to endoderm prog-
eny on Matrigel-coated polystyrene microcarriers in spinner
flasks. This method yielded a 34- to 45-fold increase in hESC
numbers in 8 days (FIPD = 4.3 to 5.6), with a definitive endodermCell Stem Cell 14, January 2, 2014 ª2014 Elsevier Inc. 21
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SOX17 and FOXA2 (Lock and Tzanakakis, 2009).
Emerging Coculture Systems for Tissue Morphogenesis
Optimal hPSC bioprocesses should, together with hPSC expan-
sion, differentiation, and cryopreservation, eventually direct
differentiation toward organogenesis. To recapitulate the devel-
opment of early vertebrate embryos, protocols call for selective
suppression and/or activation of key signaling pathways with
corresponding growth factors and small molecules under
defined culture conditions. One of the first efforts to direct differ-
entiation, with the aim of producing cardiomyocytes, was carried
out by coculture of HES-2 hESCs with visceral-endoderm-like
cells (i.e., mouse END-2 cells), which generated substantial
numbers of ventricular-like cells (Mummery et al., 2003). Cocul-
ture of monolayer ESCs with primary hepatocytes produced
homogeneous definitive endoderm-like cells, which were con-
verted to large amounts of endocrine cells (70%) on Matrigel
under retinoid induction and hedgehog inhibition. Further, cocul-
turing the endocrine cells with endothelial cells produced
approximately 60% Insulin-1-expressing cells (Banerjee et al.,
2011). However, the exact mechanism underlying pancreatic
cell maturation under these coculture conditions is not clear. It
is possible that adjacent heterogeneous cells during embryonic
development may provide suitable environmental cues tomodu-
late differentiation efficiency.
Indeed, hepatic morphogenesis depends on signal interac-
tions between endodermal (epithelial), mesenchymal, and endo-
thelial progenitors. To recapitulate early liver organogenesis,
Takebe et al. (2013) generated hepatic endodermal cells from
human iPSCs (iPSC-HEs) by directed differentiation. These
endodermal cells were cocultured with stromal cells, human
umbilical vein endothelial cells, and human mesenchymal stem
cells. These human iPSC-HEs were able to self-organize into
functional 3D liver buds (Takebe et al., 2013). This study provides
a developmental basis for establishing efficient 3D coculture
protocols.
To closely mimic the in vivo 3D ECMmicroenvironment for cell
maturation, Christman and colleagues developed a simple
method to generate tissue-specific ECM coatings by decellula-
rizing skeletal and cardiac tissues (DeQuach et al., 2010). These
decellularized matrices have been shown to facilitate the matu-
ration of committed skeletal myoblast progenitors and hESC-
derived cardiomyocytes in 3D culture (DeQuach et al., 2010).
Thus, decellularized organ scaffolds provide structural cues
and ECM components for 3D tissue morphogenesis. No doubt
these native scaffolds could be replaced by compatible bioma-
terials in the future.
To generate various neuroectodermal tissues, Sasai, Kno-
blich, and colleagues have demonstrated the feasibility of
deriving complicated tissue patterns (termed cerebral organo-
ids) through a process involving dynamic patterning and struc-
ture self-organization in 3D hPSC culture (Eiraku et al., 2008;
Lancaster et al., 2013; Nakano et al., 2012). With this approach,
they have generated distinct cortical neurons (Eiraku et al.,
2008), a 3D optic cup structure of the neural retina that contains
both rods and cones (Nakano et al., 2012), and various brain
regions containing a progenitor zone with plentiful radial glial
stem cells (Lancaster et al., 2013). Thus, these studies have22 Cell Stem Cell 14, January 2, 2014 ª2014 Elsevier Inc.paved the way to miniorganogenesis that may be used for
therapy of patients with neuronal disorders. The miniorganoids
also offer in vitro models to understand the complexity of brain
function within a culture dish. In addition, miniorganoids may
have many implications in sciences and technologies beyond
stem cell research (Sasai, 2013).
Clearly, multidimensional coculture and miniorganoids repre-
sent powerful approaches to achieve tissue and organ morpho-
genesis in vitro. With the development of a 3D coculture scaffold
and efficient protocols for hPSC expansion, differentiation, and
maturation, tissue morphogenesis and organogenesis are an
emerging resource for future tissue replacement. Spatial and
temporal control of the dynamics of intercellular interactions
in multidimensional environments would open a new era of
contemporary medicine. The caveats of the above integrated
approach for tissue engineering and organogenesis may be
somewhat complicated at the current stage, which requires a
comprehensive understanding of spatial-temporal signaling net-
works to engineer optimal 3D and/or 4D environmental cues that
efficiently regulate stem cell fate commitments.
Current Challenges and Future Directions
Pluripotent stem-cell-based therapy certainly faces many
challenges. As a treatment per se, safety is of course the
most important issue. It may be related to the quality control
of cell production under Good Manufacturing Practices
(GMP) protocols and optimization and standardization of
both cell growth media and culture methods. Without proper
quality control and standards, we may be confronted with
the impurity of the cell resource and potential tumorigenicity
of the cells during the course of cell engineering (Lee et al.,
2013). In addition, production of large numbers of functionally
mature cells with high purity at a reasonable cost is also an
important issue. An understanding of these potential problems
would provide us with future directions to address these diffi-
culties (Figure 1).
GMP-Compatible Protocols
GMP provides quality control to ensure that optimal procedures
are commonly implemented in the manufacturing industry. It
emphasizes the requirements of a manufacturing process as
standards for testing the final products (Crook et al., 2007). Gen-
eration of six clinical-grade hESC lines was initially reported in
2007 (Crook et al., 2007). Implementing GMP standards do not
necessarily guarantee that the final cell products are of
clinical-grade quality. However, it would be ideal to derive
clinical-grade cells under GMP protocols, thus ensuring repro-
ducible production of cells suitable for clinical application.
Various protocols and growth modules could be combined
with xeno-free culture methods to create clinically compatible
protocols.
Optimization and Standardization of Growth Conditions
Despite the existence of various formulations of cell culture
media, we do have common platforms emerging as standards
for guiding the formulation of the medium suitable for a precise
pluripotent or cellular state. These standards are based on the
understanding of core signaling pathways that sustain optimal
stem cell growth and direct uniform differentiation (Hanna
et al., 2010; Nichols and Smith, 2009). The potential challenges
are: (1) we need to determine the long-term effects of several
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also need to vigorously verify the preclinical safety and efficacy
of final cell products derived in vitro or ex vivo, and (3) the final
cell products derived from cell culture need to show anticipated
safety and desired functionality in patients. Importantly, clinical
information from patients would feed back to confirm or revise
our culture medium formulations as well as growth modes and
environmental cues. Without the above information in hand, we
believe that we have only achieved a certain capacity to culture
and differentiate hPSCs at a preclinical level, but not yet in a
clinical setting.
Economic Considerations of hPSC Resources and
Processing
The economics of cell processing and of obtaining desired
cell resources are likely to have considerable impact on
hPSC-based therapies. Obtaining clinically relevant numbers
of functionally mature cells is a big challenge in the field
of stem cell engineering. Practically, we need to seriously
consider the cost at every stage from cell derivation to clinical
trials. In the following sections, we will discuss some general
considerations for cell expansion and scaling up culture of
differentiated cells.
General Considerations for Cell Expansion.With regard to cell
processing, any approach that reduces cost, whether in terms
of cell culture modules or labor costs, will be relevant to the
industrial scale production of undifferentiated cells and their
differentiated progeny. For example, scale-up in bioreactors
may save on costly substrates but equipment may be more
expensive to obtain and maintain. It is also important to
note that the scale-up method should not deviate significantly
from that used in the laboratories because culture methods in-
fluence the differentiation potential of the cells. Additionally,
time taken to reach target numbers, incubator space, and
any special parameters required (such as low O2) should also
be considered. It is also important to consider media and
culture optimization to improve time required to reach target
cell numbers. In terms of cost, it would seem likely that a
synthetic product may be easier to produce compared with
the purification of a complicated macromolecule (e.g., growth
factors). This is relevant both in terms of small molecules
versus growth factors and a synthetic substrate versus a puri-
fied ECM component.
Concerning Scaling Up Cultures with Differentiation Protocols.
Manufacturing large numbers of functionally differentiated cell
types with homogeneous cellular states (at a reasonable cost)
represents a limiting step to both the research and therapeutic
use of hPSCs. However, the mature cells are usually difficult to
amplify due to low proliferation rates. If the desired terminally
differentiated cell type has a corresponding proliferative interme-
diate, then it may not be necessary to scale up the pluripotent
population and the onus shifts to scale up the differentiated pre-
cursors. However, many desired cell types, such as osteoblasts
and chondroblasts, do not have a suitable proliferative interme-
diate. In this case, we may need to start with a large number of
hPSCs and then couple these pluripotent cells with differentia-
tion protocols when a desired therapy is scheduled. We believe
that linking cell expansion strategies to the proliferation features
of differentiated cells would have a significant impact on saving
unnecessary costs.Conclusions
Various methods based on colony culture, non-colony types of
cell growth, and aggregated suspension culture can be used to
culture hPSCs. Thesemethodsmaintain the epithelial character-
istics of hPSCs under defined feeder, feeder-free, and xeno-free
conditions. Many novel culture protocols appear to be robust
and scalable, making them potential candidates to generate
clinical-grade hPSCs and their derivative tissues to serve the
purposes of regenerative medicine. With further modifications
of the existing methods, efficient production of clinically relevant
quantities of hPSCs could be attainable for both stem-cell-based
therapies and high-throughput drug discovery.ACKNOWLEDGMENTS
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